Compare UMH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | SANA |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | UMH | SANA |
|---|---|---|
| Price | $15.88 | $5.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $17.75 | $7.83 |
| AVG Volume (30 Days) | 641.3K | ★ 5.2M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $256,272,000.00 | N/A |
| Revenue This Year | $10.80 | N/A |
| Revenue Next Year | $8.34 | N/A |
| P/E Ratio | $203.10 | ★ N/A |
| Revenue Growth | ★ 8.96 | N/A |
| 52 Week Low | $13.95 | $1.26 |
| 52 Week High | $19.75 | $7.30 |
| Indicator | UMH | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 62.45 |
| Support Level | $14.96 | $4.25 |
| Resistance Level | $15.51 | $5.43 |
| Average True Range (ATR) | 0.25 | 0.50 |
| MACD | 0.08 | 0.14 |
| Stochastic Oscillator | 85.60 | 89.74 |
UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.